Welcome to our dedicated page for EUCR news (Ticker: EUCR), a resource for investors and traders seeking the latest updates and insights on EUCR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EUCR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EUCR's position in the market.
Eucrates Biomedical Acquisition Corp. (NASDAQ: EUCR) announced on April 11, 2023, that it will dissolve and liquidate following its inability to complete an initial business combination within the required timeframe. The company will redeem all outstanding ordinary shares at approximately $10.00 per share, effective April 26, 2023. Holders of Public Shares must deliver their shares to redeem their pro-rata portion from the trust account, which will be liquidated for this purpose. After the redemption, the shares will be canceled, and the company will file to delist its securities from the Nasdaq Capital Market and terminate the registration under the Securities Exchange Act of 1934. This marks a significant development for shareholders, who will receive their funds but will see the company exit the public market.
Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) announced it received a notice from Nasdaq for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021. The notice does not affect the current listing or trading of its securities. Following guidance from the SEC on accounting for warrants, the Company is reevaluating its financial statements and aims to submit its Form 10-Q promptly. It has 60 days to present a compliance plan, with the potential for an extension of up to 180 days.
FAQ
What is the market cap of EUCR (EUCR)?
